MISSION Therapeutics
Mission is a privately-held UK drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs).
There is optimism in Mission’s work in neurodegenerative conditions, in particular, because DUBs play an important role in keeping a cell healthy by regulating the degradation of the misfolded, toxic proteins that are believed to cause impaired function and death of nerve cells in the brain.
The company signed a collaboration in this area with US drugmaker AbbVie in November, 2018.
Latest MISSION Therapeutics News & Features
9 August 2021
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze